MA29813B1 - Combinaisons pharmaceutiques contenant de la lamivudine, de la stavudine et de la nevirapine - Google Patents

Combinaisons pharmaceutiques contenant de la lamivudine, de la stavudine et de la nevirapine

Info

Publication number
MA29813B1
MA29813B1 MA30791A MA30791A MA29813B1 MA 29813 B1 MA29813 B1 MA 29813B1 MA 30791 A MA30791 A MA 30791A MA 30791 A MA30791 A MA 30791A MA 29813 B1 MA29813 B1 MA 29813B1
Authority
MA
Morocco
Prior art keywords
stavudine
nevirapine
lamivudine
pharmaceutical combinations
combinations containing
Prior art date
Application number
MA30791A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MA29813B1 publication Critical patent/MA29813B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION DÉCRIT UNE PRÉPARATION PHARMACEUTIQUE COMPRENANT ENTRE 10 ET 120 MG DE LAMIVUDINE, ENTRE 1 ET 30 MG DE STAVUDINE ET ENTRE 50 ET 170 MG DE NÉVIRAPINE POUR LE TRAITEMENT PÉDIATRIQUE D'INFECTIONS VIRALES. UNE PRÉPARATION PARTICULIÈREMENT PRÉFÉRÉE COMPREND UN COMPRIMÉ CONTENANT 12 MG DE STAVUDINE, 60 MG DE LAMIVUDINE ET 100 MG DE NÉVIRAPINE. UNE AUTRE PRÉPARATION PARTICULIÈREMENT PRÉFÉRÉE COMPREND UN SECOND COMPRIMÉ CONTENANT 6 MG DE STAVUDINE, 30 MG DE LAMIVUDINE ET 500 MG DE NÉVIRAPINE. CES PRÉPARATIONS SONT ADAPTÉES AU TRAITEMENT D'ENFANTS DONT LA MASSE CORPORELLE EST COMPRISE ENTRE 5 ET 30 KG.
MA30791A 2005-08-31 2008-03-31 Combinaisons pharmaceutiques contenant de la lamivudine, de la stavudine et de la nevirapine MA29813B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1057MU2005 2005-08-31

Publications (1)

Publication Number Publication Date
MA29813B1 true MA29813B1 (fr) 2008-09-01

Family

ID=37442043

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30791A MA29813B1 (fr) 2005-08-31 2008-03-31 Combinaisons pharmaceutiques contenant de la lamivudine, de la stavudine et de la nevirapine

Country Status (14)

Country Link
US (1) US20080241265A1 (fr)
EP (1) EP1931358B1 (fr)
KR (1) KR20080053317A (fr)
AP (1) AP2008004389A0 (fr)
AT (1) ATE484284T1 (fr)
AU (1) AU2006286314A1 (fr)
BR (1) BRPI0617074A2 (fr)
CA (1) CA2620853A1 (fr)
DE (1) DE602006017569D1 (fr)
ES (1) ES2352216T3 (fr)
MA (1) MA29813B1 (fr)
NZ (1) NZ566796A (fr)
WO (1) WO2007026156A1 (fr)
ZA (1) ZA200802751B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866133A1 (fr) * 2012-03-05 2013-09-12 Cipla Limited Combinaisons pharmaceutiques antiretrovirales comprenant de la lamivudine, du festinavir et de la nevirapine
CN104677786B (zh) * 2015-03-09 2017-07-18 上海理工大学 一种基于双目3d视觉的休止角测量方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5616578A (en) * 1993-08-26 1997-04-01 The Dupont Merck Pharmaceutical Company Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
ES2265666T3 (es) * 1997-08-25 2007-02-16 Boehringer Ingelheim Pharmaceuticals Inc. Suspension farmaceutica que comprende hemihidrato de nevirapina.
BR9906933A (pt) * 1998-01-16 2001-11-27 Medivir Ab Antiviróticos
CA2404687A1 (fr) * 2000-03-30 2001-10-11 Nemichand B. Jain Granules a liberation lente contenant de la stavudine
IT1318463B1 (it) * 2000-04-12 2003-08-25 Archimica S P A Ora Clariant L Procedimento per la preparazione di 5'-acetilstavudina.

Also Published As

Publication number Publication date
AU2006286314A1 (en) 2007-03-08
CA2620853A1 (fr) 2007-03-08
EP1931358B1 (fr) 2010-10-13
WO2007026156A1 (fr) 2007-03-08
NZ566796A (en) 2011-04-29
DE602006017569D1 (de) 2010-11-25
BRPI0617074A2 (pt) 2011-07-12
KR20080053317A (ko) 2008-06-12
EP1931358A1 (fr) 2008-06-18
US20080241265A1 (en) 2008-10-02
ES2352216T3 (es) 2011-02-16
ZA200802751B (en) 2009-07-29
AP2008004389A0 (en) 2008-04-30
ATE484284T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
MA28740B1 (fr) Methodes de traitement d'infections endobronchiques
EP2213684A3 (fr) Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
MXPA03008955A (es) Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez.
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
EP2517721A3 (fr) Traitement de maladies à mediation des lymphocytes T
IL152807A0 (en) Protein kinase inhibitors
IT1318539B1 (it) Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
WO2004014953A3 (fr) Anticorps
WO2003018635A1 (fr) Anticorps greffes cdr humains et fragments de ces anticorps
JP2007522094A5 (fr)
MA27087A1 (fr) Compositions pharmaceutiques comprenant le glibenclamide et la metformine destinees au traitement du diabete sucre de type ii
MA26757A1 (fr) Preparation pharmaceutique de moxifloxacine
WO2001092283A3 (fr) Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie
WO2008016431A3 (fr) Médicament thérapeutique d'anticorps monoclonal bispécifique ( spécifique à la fois à cd3 et cd11b)
MA27927A1 (fr) Preparations pharmaceutiques
SI1622939T1 (sl) Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
WO2006021160A8 (fr) Système de relargage de médicament auto-émulsifiant à base de butylbenzènephtaléine, méthode de préparation et applications d’un tel système
WO2005063219A3 (fr) Capsules en gelatine molle contenant de l'ibuprofene
EA200700158A1 (ru) Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
SI1765337T1 (sl) Kombinacija tenofovirja, ritonavirja in TMC114
WO2002102318A3 (fr) Medicaments a base d'egline c utilises dans le traitement de maladies
EP0955366A4 (fr) Proteine antigenique provenant de la malassezia